About Virvio

About company

Virvio is a pre-clinical biotherapeutic company developing a broadly-neutralizing peptide capable of both pre- and post- exposure containment of influenza. The drug candidate is being developed as a shelf-stable, single-dose, inhaled product suitable for stockpiling and global pandemic preparedness.